DepYmed Receives European Medicines Agency Orphan Drug Designation for Its Lead Clinical Candidate for the Treatment of Rett ...
FARMINGDALE, N.Y., Nov. 16, 2022 (GLOBE NEWSWIRE) -- DepYmed, Inc. ("DepYmed" or the "Company") is a preclinical stage pharmaceutical company focused on developing transformative treatments for rare diseases and oncology based upon …